Over the past couple of decades, the exponential progress of sequencing technologies has allowed an increasing number of cancer patients to benefit from precision oncology. However, the aggregation, analysis, and visualization of the massive amounts of genomic data remain a major challenge for precision oncology expansion. The Epigene Labs technology platform enables cancer drug hunters to seamlessly leverage advanced Artificial Intelligence in transforming genomic data into actionable insights for designing precision oncology approaches. With R&D in Paris and business development in Boston, Epigene Labs operates in the setting of value-based partnerships with world-leading cancer centers and high-profile biotechs.